Topics

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Zentiva, emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 09/11/2016, Revision: 3, Status: Authorised

08:00 EDT 3 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Zentiva, emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 09/11/2016, Revision: 3, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Zentiva, emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 09/11/2016, Revision: 3, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Zentiva, emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 09/11/2016, Revision: 3, Status: Authorised"

Quick Search

Relevant Topics

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...

AIDS and HIV
AIDS; Acquired Immune Deficiency Syndrome. HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, which forms the test for HIV in patients. People who have the HIV antibodies are ...